AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29341461 — intervention group
Group type: COMPARATOR
Intervention: Exenatide infusion (Study-A)
Number of subjects: 132
Study 29341461 — intervention group
Group type: COMPARATOR
Intervention: Exenatide infusion (Study-B)
Number of subjects: 132
Study 29341461 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide (Study-C)
Number of subjects: 132
Study 29341461 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (Study-D)
Number of subjects: 132
Study 24380501 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component educational intervention (small media, academic detailing, and website for providers; printed educational materials for patients)
Number of subjects: 2246
Study 24380501 — intervention group
Group type: COMPARATOR
Intervention: Printed copies of general guidelines
Number of subjects: 2246
Study 22622291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg)
Number of subjects: 48
Study 22622291 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus Ketamine (1.5 mg/kg + 0.8 mg/kg)
Number of subjects: 48
Study 22622291 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1.5 mg/kg)
Number of subjects: 48
Study 20394542 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anti-glaucoma medications (AGM)
Number of subjects: 96
Study 20394542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no topical medications)
Number of subjects: 96
Study 18588760 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 14
Study 18588760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18588760 — intervention group
Group type: EXPERIMENTAL
Intervention: Local decongestant
Number of subjects: 14
Study 18588760 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil + Local decongestant
Number of subjects: 14
Study 15965687 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body (18)F‐FDG PET after one or two courses of induction chemotherapy (IC)
Number of subjects: 50
Study 15965687 — intervention group
Group type: EXPERIMENTAL
Intervention: Major responders (downstaged to stage I or II)
Number of subjects: 50
Study 12069285 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture (TCA)
Number of subjects: 20
Study 12069285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear acupuncture (EA)
Number of subjects: 20
Study 12069285 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean hand acupuncture (KHA)
Number of subjects: 20
Study 12069285 — intervention group
Group type: COMPARATOR
Intervention: Placebo needling (PN)
Number of subjects: 20
Study 10520784 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt cessation of intravenous unfractionated heparin (UFH)
Number of subjects: 30
Study 10520784 — intervention group
Group type: COMPARATOR
Intervention: Intravenous weaning over 12 hours
Number of subjects: 30
Study 10520784 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous weaning over 12 hours
Number of subjects: 30
Study 7830033 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10
Study 7830033 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 10
Study 7830033 — intervention group
Group type: COMPARATOR
Intervention: Enalapril and Doxazosin
Number of subjects: 10
Study 2115686 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Novo Protaphan HM Penfill (100 IU/ml 'bed time') and 10 mg of glibenclamide in the morning (group A)
Number of subjects: 28
Study 2115686 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Novo Actraphan HM Penfill (100 IU/ml in the morning) combined with two 5 mg doses of glibenclamide at lunchtime and in the evening (group B)
Number of subjects: 28
Study 2115686 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide dropout period
Number of subjects: 28
Study 844351 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 checkerboards
Number of subjects: 0
Study 844351 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 checkerboards
Number of subjects: 0
Study 844351 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 checkerboards
Number of subjects: 0
Study 31915696 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32
Study 31915696 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 32
Study 29735813 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tyrosine (100 mg/kg/day)
Number of subjects: 19
Study 29735813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 26048342 — intervention group
Group type: EXPERIMENTAL
Intervention: Schisandra chinensis fruit (SCF)
Number of subjects: 28
Study 26048342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23926751 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone coaching intervention
Number of subjects: 0
Study 21798407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% mitomycin C (MMC) applied intra-operatively for 30 seconds over the ablated zone
Number of subjects: 64
Study 21798407 — intervention group
Group type: COMPARATOR
Intervention: No mitomycin C (MMC)
Number of subjects: 64
Study 21798407 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CCT changes between groups 1 and 2
Number of subjects: 64
Study 19564995 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMER (Tool to Improve Medications in the Elderly via Review)
Number of subjects: 244
Study 16229010 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/day
Number of subjects: 433
Study 16229010 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine (for placebo patients switching)
Number of subjects: 433
Study 16229010 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 433
Study 15327641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with mouthrinses formulated with chlorhexidine, cetylpyridinium chloride or triclosan/copolymer
Number of subjects: 0
Study 15327641 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with a triclosan/copolymer dentifrice
Number of subjects: 0
Study 15327641 — intervention group
Group type: EXPERIMENTAL
Intervention: Rinsing with a sucrose solution
Number of subjects: 0
Study 15327641 — intervention group
Group type: COMPARATOR
Intervention: Rinsing with water, a commercially available fluoride mouthrinse without antimicrobial agents, or brushing with a fluoride dentifrice
Number of subjects: 0
Study 15327641 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinses
Number of subjects: 0
Study 11194173 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsules containing 300 mg of alcoholic Hypericum extract (5% hyperforin and 0.3% hypericin)
Number of subjects: 12
Study 11194173 — intervention group
Group type: COMPARATOR
Intervention: Hard gelatin capsules (standard formulation)
Number of subjects: 12
Study 11194173 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsules
Number of subjects: 12
Study 9313185 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-Fowler's position with left lateral tilt
Number of subjects: 573
Study 9313185 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-Fowler's position with right lateral tilt
Number of subjects: 573
Study 9313185 — intervention group
Group type: COMPARATOR
Intervention: Semi-Fowler's position without lateral tilt (Control)
Number of subjects: 573
Study 8489054 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (1 micrograms/kg)
Number of subjects: 38
Study 8489054 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (0.05 micrograms/kg)
Number of subjects: 38
Study 2442553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 40-80 mg/day
Number of subjects: 115
Study 2442553 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100-200 mg/day
Number of subjects: 115
Study 29799871 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-time chlorhexidine (CHG-T1)
Number of subjects: 2349
Study 29799871 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-time chlorhexidine (CHG-T4)
Number of subjects: 2349
Study 29799871 — intervention group
Group type: COMPARATOR
Intervention: 1-time povidone iodine (PVI-T1)
Number of subjects: 2349
Study 29799871 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-time povidone iodine (PVI-T4)
Number of subjects: 2349
Study 26525271 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels measured on days 1, 2, and 3 after return of spontaneous circulation
Number of subjects: 682
Study 26525271 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels at day 2
Number of subjects: 682
Study 26525271 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels at day 3
Number of subjects: 682
Study 26525271 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 682
Study 24001004 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral reaction times (RTs) for categorizing objects
Number of subjects: 0
Study 22236346 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine (40 mg) mixed with 12.5 μg of fentanyl
Number of subjects: 40
Study 22236346 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (35 mg) mixed with 12.5 μg of fentanyl
Number of subjects: 40
Study 20350785 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg orally twice per day starting on the day of implant
Number of subjects: 316
Study 20350785 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg orally twice per day starting 1 week prior to implant
Number of subjects: 316
Study 20350785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no meloxicam)
Number of subjects: 316
Study 18410298 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 117
Study 18410298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 117
Study 18410298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil plus Counseling
Number of subjects: 117
Study 17274381 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic idarubicin
Number of subjects: 155
Study 17274381 — intervention group
Group type: COMPARATOR
Intervention: Imported idarubicin
Number of subjects: 155
Study 12885371 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX) 60 mg daily for 12 months
Number of subjects: 204
Study 12885371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 12885371 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (RLX)
Number of subjects: 204
Study 11081960 — intervention group
Group type: EXPERIMENTAL
Intervention: CIBIC-Plus (Clinician Interview-Based Impression of Change)
Number of subjects: 0
Study 8897116 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 20
Study 8897116 — intervention group
Group type: COMPARATOR
Intervention: Drug-free depressed patients
Number of subjects: 20
Study 1796634 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 synthesis stimulation
Number of subjects: 0
Study 1796634 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of cyclooxygenase
Number of subjects: 0
Study 1796634 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate heart failure
Number of subjects: 0
Study 1796634 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe heart failure
Number of subjects: 0
Study 6615751 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiprostaglandins
Number of subjects: 0
Study 6615751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31613308 — intervention group
Group type: EXPERIMENTAL
Intervention: Selepressin
Number of subjects: 0
Study 31613308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30153634 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 55
Study 30153634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 27169811 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week ESM intervention including feedback
Number of subjects: 90
Study 27169811 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week ESM intervention without feedback
Number of subjects: 90
Study 27169811 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 90
Study 24461278 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled Breathing (CB)
Number of subjects: 196
Study 24461278 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint Aromatherapy (AR)
Number of subjects: 196
Study 24461278 — intervention group
Group type: COMPARATOR
Intervention: Control (CB)
Number of subjects: 196
Study 22916626 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Auditory Training (MAT)
Number of subjects: 100
Study 22916626 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 100
Study 19291120 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Number of subjects: 80
Study 19291120 — intervention group
Group type: COMPARATOR
Intervention: Silver sulphadiazine (SD‐Ag)
Number of subjects: 80
Study 17699835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine booster
Number of subjects: 386
Study 15319388 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching using acidic Tyrode's solution
Number of subjects: 253
Study 15319388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no assisted hatching)
Number of subjects: 253
Study 15319388 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 253
Study 11453889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) 0.5 mg
Number of subjects: 10
Study 9509448 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 20
Study 9509448 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate haemodialysis (HD)
Number of subjects: 20
Study 7798824 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumadin (adjusted dosage to maintain INR between 1.5-3)
Number of subjects: 79
Study 7798824 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (fixed dosage of 75 mg per day)
Number of subjects: 79
Study 3183367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride (120 mmol)
Number of subjects: 6
Study 3183367 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate (122 mmol)
Number of subjects: 6
Study 31816097 — intervention group
Group type: EXPERIMENTAL
Intervention: eIL-31-CuMVTT vaccine (300 µg)
Number of subjects: 18
Study 31816097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29991223 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp block
Number of subjects: 60
Study 29991223 — intervention group
Group type: COMPARATOR
Intervention: Incision-site infiltration
Number of subjects: 60
Study 26554758 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/day of alcohol
Number of subjects: 53
Study 26554758 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day of alcohol
Number of subjects: 53
Study 26554758 — intervention group
Group type: COMPARATOR
Intervention: 0 g/day of alcohol (control)
Number of subjects: 53
Study 26333496 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling (8 sessions over 2 months)
Number of subjects: 100
Study 26333496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 100
Study 24346133 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-eicosapentaenoate (EPA) 2g/day
Number of subjects: 99
Study 24346133 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins E (364mg/day) + C (1000mg/day)
Number of subjects: 99
Study 24346133 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA + Vitamins E+C
Number of subjects: 99
Study 24346133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 24346133 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and Vitamins E+C (given separately)
Number of subjects: 99
Study 24346133 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and Vitamins E+C (combined)
Number of subjects: 99
Study 24346133 — intervention group
Group type: EXPERIMENTAL
Intervention: High PUFA patients
Number of subjects: 99
Study 21613574 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐AR blockade (intravenous propranolol)
Number of subjects: 6
Study 21613574 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 6
Study 18468672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with 525 microg of venom monthly after a 6-week build-up period
Number of subjects: 30
Study 18468672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17050873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 112
Study 17050873 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 112
Study 12747499 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/day for 4 weeks
Number of subjects: 30
Study 12747499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11125657 — intervention group
Group type: EXPERIMENTAL
Intervention: Post deliberation jurors
Number of subjects: 0
Study 8648920 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 20
Study 1552057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UVA1 irradiation (130 joules/cm2)
Number of subjects: 25
Study 1552057 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UVA1 irradiation
Number of subjects: 25
Study 1552057 — intervention group
Group type: COMPARATOR
Intervention: UVA-UVB therapy
Number of subjects: 25
Study 6496201 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased nicotine content cigarettes
Number of subjects: 0
Study 6496201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low yield cigarettes
Number of subjects: 0
Study 6496201 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to standard brand cigarettes
Number of subjects: 0
Study 31718019 — intervention group
Group type: EXPERIMENTAL
Intervention: School physical education intervention (SPE)
Number of subjects: 680
Study 31718019 — intervention group
Group type: EXPERIMENTAL
Intervention: Afterschool program intervention (ASP)
Number of subjects: 680
Study 31718019 — intervention group
Group type: EXPERIMENTAL
Intervention: SPE + ASP
Number of subjects: 680
Study 31718019 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 680
Study 31143214 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and lifestyle-related educations
Number of subjects: 54
Study 31143214 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle-related educations
Number of subjects: 54
Study 27418241 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) + Methotrexate (MTX)
Number of subjects: 21
Study 27418241 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 21
Study 25223240 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants with birth and newborn care preparedness
Number of subjects: 32126
Study 25223240 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants with symptoms of infection
Number of subjects: 32126
Study 25223240 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants whose mother suffered antenatal complications
Number of subjects: 32126
Study 25223240 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm births overall
Number of subjects: 32126
Study 25223240 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants born as the first child
Number of subjects: 32126
Study 25223240 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants in the poorest households
Number of subjects: 32126
Study 22149257 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of fluindione
Number of subjects: 24
Study 22149257 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of acenocoumarol
Number of subjects: 24
Study 22149257 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9 genotype, VKORC1 genotype, body weight
Number of subjects: 24
Study 22149257 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9 genotype, VKORC1 genotype, CYP1A2 phenotype, body weight
Number of subjects: 24
Study 20669294 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT®BIG (one-to-one training)
Number of subjects: 60
Study 20669294 — intervention group
Group type: COMPARATOR
Intervention: Nordic Walking (WALK)
Number of subjects: 60
Study 20669294 — intervention group
Group type: COMPARATOR
Intervention: Domestic nonsupervised exercises (HOME)
Number of subjects: 60
Study 18794727 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARgamma agonists (muraglitazar and other 10 PPARgamma agonists)
Number of subjects: 730
Study 18794727 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARgamma agonists (one of three previously uncharacterized PPARgamma agonists)
Number of subjects: 730
Study 15765299 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 14
Study 15765299 — intervention group
Group type: COMPARATOR
Intervention: Historical group (pre‐imatinib era)
Number of subjects: 14
Study 12127877 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 as adjunctive therapy to antiretroviral therapy
Number of subjects: 0
Study 12127877 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 0
Study 10772563 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed administration of DTPw-HBV and Hib vaccines
Number of subjects: 0
Study 10772563 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of DTPw-HBV and Hib vaccines
Number of subjects: 0
Study 10772563 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of Hib to DTPw-HBV
Number of subjects: 0
Study 8545872 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid Withdrawal (SW) group
Number of subjects: 64
Study 8545872 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 8545872 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 2403486 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice containing 250 ppm fluoride
Number of subjects: 1161